Osteopontin is a prognostic biomarker in non-small cell lung cancer
Abstract Background In a previously published report we characterized the expression of the metastasis-associated proteins S100A4, osteopontin (OPN) and ephrin-A1 in a prospectively collected panel of non-small cell lung cancer (NSCLC) tumors. The aim of the present follow-up study was to investigat...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2013-11-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/1471-2407-13-540 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850109989468766208 |
|---|---|
| author | Ane Kongsgaard Kjetil Boye Miriam Øijordsbakken Marius Lund-Iversen Ann Rita Halvorsen Steinar K Solberg Gisle Berge Åslaug Helland Odd Terje Brustugun Gunhild M Mælandsmo |
| author_facet | Ane Kongsgaard Kjetil Boye Miriam Øijordsbakken Marius Lund-Iversen Ann Rita Halvorsen Steinar K Solberg Gisle Berge Åslaug Helland Odd Terje Brustugun Gunhild M Mælandsmo |
| author_sort | Ane Kongsgaard |
| collection | DOAJ |
| description | Abstract Background In a previously published report we characterized the expression of the metastasis-associated proteins S100A4, osteopontin (OPN) and ephrin-A1 in a prospectively collected panel of non-small cell lung cancer (NSCLC) tumors. The aim of the present follow-up study was to investigate the prognostic impact of these potential biomarkers in the same patient cohort. In addition, circulating serum levels of OPN were measured and single nucleotide polymorphisms (SNP) in the -443 position of the OPN promoter were analyzed. Methods Associations between immunohistochemical expression of S100A4, OPN and ephrin-A1 and relapse free and overall survival were examined using univariate and multivariate analyses. Serum OPN was measured by ELISA, polymorphisms in the -443 position of the tumor OPN promoter were analyzed by PCR, and associations between OPN levels and promoter polymorphisms and clinicopathological parameters and patient outcome were investigated. Results High expression of OPN in NSCLC tumors was associated with poor patient outcome, and OPN was a strong, independent prognostic factor for both relapse free and overall survival. Serum OPN levels increased according to tumor pT classification and tumor size, and patients with OPN-expressing tumors had higher serum levels than patients with OPN-negative tumors. S100A4 was a negative prognostic factor in several subgroups of adenocarcinoma patients, but not in the overall patient cohort. There was no association between ephrin-A1 expression and patient outcome. Conclusions OPN is a promising prognostic biomarker in NSCLC, and should be further explored in the selection of patients for adjuvant treatment following surgical resection. |
| format | Article |
| id | doaj-art-25115c85ff54446898a8cc99f6ed02c0 |
| institution | OA Journals |
| issn | 1471-2407 |
| language | English |
| publishDate | 2013-11-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj-art-25115c85ff54446898a8cc99f6ed02c02025-08-20T02:37:57ZengBMCBMC Cancer1471-24072013-11-0113111010.1186/1471-2407-13-540Osteopontin is a prognostic biomarker in non-small cell lung cancerAne Kongsgaard0Kjetil Boye1Miriam Øijordsbakken2Marius Lund-Iversen3Ann Rita Halvorsen4Steinar K Solberg5Gisle Berge6Åslaug Helland7Odd Terje Brustugun8Gunhild M Mælandsmo9Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University HospitalDepartment of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University HospitalDepartment of Medical Biochemistry, The Norwegian Radium Hospital, Oslo University HospitalDepartment of Pathology, The Norwegian Radium Hospital, Oslo University HospitalDepartment of Genetics, Institute for Cancer Research, The Norwegian Radium, Hospital, Oslo University HospitalDepartment of Cardiovascular and Thoracic Surgery, Rikshospitalet, Oslo University HospitalDepartment of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University HospitalDepartment of Oncology, The Norwegian Radium Hospital, Oslo University HospitalDepartment of Oncology, The Norwegian Radium Hospital, Oslo University HospitalDepartment of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University HospitalAbstract Background In a previously published report we characterized the expression of the metastasis-associated proteins S100A4, osteopontin (OPN) and ephrin-A1 in a prospectively collected panel of non-small cell lung cancer (NSCLC) tumors. The aim of the present follow-up study was to investigate the prognostic impact of these potential biomarkers in the same patient cohort. In addition, circulating serum levels of OPN were measured and single nucleotide polymorphisms (SNP) in the -443 position of the OPN promoter were analyzed. Methods Associations between immunohistochemical expression of S100A4, OPN and ephrin-A1 and relapse free and overall survival were examined using univariate and multivariate analyses. Serum OPN was measured by ELISA, polymorphisms in the -443 position of the tumor OPN promoter were analyzed by PCR, and associations between OPN levels and promoter polymorphisms and clinicopathological parameters and patient outcome were investigated. Results High expression of OPN in NSCLC tumors was associated with poor patient outcome, and OPN was a strong, independent prognostic factor for both relapse free and overall survival. Serum OPN levels increased according to tumor pT classification and tumor size, and patients with OPN-expressing tumors had higher serum levels than patients with OPN-negative tumors. S100A4 was a negative prognostic factor in several subgroups of adenocarcinoma patients, but not in the overall patient cohort. There was no association between ephrin-A1 expression and patient outcome. Conclusions OPN is a promising prognostic biomarker in NSCLC, and should be further explored in the selection of patients for adjuvant treatment following surgical resection.https://doi.org/10.1186/1471-2407-13-540NSCLCPrognosisBiomarkerOsteopontinS100A4 |
| spellingShingle | Ane Kongsgaard Kjetil Boye Miriam Øijordsbakken Marius Lund-Iversen Ann Rita Halvorsen Steinar K Solberg Gisle Berge Åslaug Helland Odd Terje Brustugun Gunhild M Mælandsmo Osteopontin is a prognostic biomarker in non-small cell lung cancer BMC Cancer NSCLC Prognosis Biomarker Osteopontin S100A4 |
| title | Osteopontin is a prognostic biomarker in non-small cell lung cancer |
| title_full | Osteopontin is a prognostic biomarker in non-small cell lung cancer |
| title_fullStr | Osteopontin is a prognostic biomarker in non-small cell lung cancer |
| title_full_unstemmed | Osteopontin is a prognostic biomarker in non-small cell lung cancer |
| title_short | Osteopontin is a prognostic biomarker in non-small cell lung cancer |
| title_sort | osteopontin is a prognostic biomarker in non small cell lung cancer |
| topic | NSCLC Prognosis Biomarker Osteopontin S100A4 |
| url | https://doi.org/10.1186/1471-2407-13-540 |
| work_keys_str_mv | AT anekongsgaard osteopontinisaprognosticbiomarkerinnonsmallcelllungcancer AT kjetilboye osteopontinisaprognosticbiomarkerinnonsmallcelllungcancer AT miriamøijordsbakken osteopontinisaprognosticbiomarkerinnonsmallcelllungcancer AT mariuslundiversen osteopontinisaprognosticbiomarkerinnonsmallcelllungcancer AT annritahalvorsen osteopontinisaprognosticbiomarkerinnonsmallcelllungcancer AT steinarksolberg osteopontinisaprognosticbiomarkerinnonsmallcelllungcancer AT gisleberge osteopontinisaprognosticbiomarkerinnonsmallcelllungcancer AT aslaughelland osteopontinisaprognosticbiomarkerinnonsmallcelllungcancer AT oddterjebrustugun osteopontinisaprognosticbiomarkerinnonsmallcelllungcancer AT gunhildmmælandsmo osteopontinisaprognosticbiomarkerinnonsmallcelllungcancer |